Brief communication: β-cell function influences dopamine receptor availability
Julia P Dunn, Naji N Abumrad, Bruce W Patterson, Robert M Kessler, Robyn A Tamboli, Julia P Dunn, Naji N Abumrad, Bruce W Patterson, Robert M Kessler, Robyn A Tamboli
Abstract
We aim to identify physiologic regulators of dopamine (DA) signaling in obesity but previously did not find a compelling relationship with insulin sensitivity measured by oral-minimal model (OMM) and DA subtype 2 and 3 receptor (D2/3R) binding potential (BPND). Reduced disposition index (DI), a β-cell function metric that can also be calculated by OMM, was shown to predict a negative reward behavior that occurs in states of lower endogenous DA. We hypothesized that reduced DI would occur with higher D2/3R BPND, reflecting lower endogenous DA. Participants completed PET scanning, with a displaceable radioligand to measure D2/3R BPND, and a 5-hour oral glucose tolerance test to measure DI by OMM. We studied 26 age-similar females without (n = 8) and with obesity (n = 18) (22 vs 39 kg/m2). Reduced DI predicted increased striatal D2/3R BPND independent of BMI. By accounting for β-cell function, we were able to determine that the state of insulin and glucose metabolism is pertinent to striatal D2/3R BPND in obesity. Clinical Trial Registration Number: NCT00802204.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures
![Fig 1. Linear regressions for striatal D2/3R…](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6407783/bin/pone.0212738.g001.jpg)
![Fig 2. Presynaptic terminal: Simplified schema of…](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6407783/bin/pone.0212738.g002.jpg)
References
- Murray S, Tulloch A, Gold MS, Avena NM. Hormonal and neural mechanisms of food reward, eating behaviour and obesity. Nat Rev Endocrinol. 2014;10(9):540–52. 10.1038/nrendo.2014.91 .
- Speed N, Saunders C, Davis AR, Owens WA, Matthies HJ, Saadat S, et al. Impaired striatal Akt signaling disrupts dopamine homeostasis and increases feeding. PLoS One. 2011;6(9):e25169 10.1371/journal.pone.0025169
- Dunn JP, Kessler RM, Feurer ID, Volkow ND, Patterson BW, Ansari MS, et al. Relationship of dopamine type 2 receptor binding potential with fasting neuroendocrine hormones and insulin sensitivity in human obesity. Diabetes care. 2012;35(5):1105–11. 10.2337/dc11-2250
- Geiger BM, Haburcak M, Avena NM, Moyer MC, Hoebel BG, Pothos EN. Deficits of mesolimbic dopamine neurotransmission in rat dietary obesity. Neuroscience. 2009;159(4):1193–9. 10.1016/j.neuroscience.2009.02.007
- van de Giessen E, Celik F, Schweitzer DH, van den Brink W, Booij J. Dopamine D2/3 receptor availability and amphetamine-induced dopamine release in obesity. J Psychopharmacol. 2014;28(9):866–73. 10.1177/0269881114531664 .
- Guo J, Simmons WK, Herscovitch P, Martin A, Hall KD. Striatal dopamine D2-like receptor correlation patterns with human obesity and opportunistic eating behavior. Mol Psychiatry. 2014;19(10):1078–84. Epub 2014/09/10. 10.1038/mp.2014.102
- Dang LC, Samanez-Larkin GR, Castrellon JJ, Perkins SF, Cowan RL, Zald DH. Associations between dopamine D2 receptor availability and BMI depend on age. NeuroImage. 2016;138:176–83. Epub 2016/05/22. 10.1016/j.neuroimage.2016.05.044
- Eisenstein SA, Gredysa DM, Antenor-Dorsey JA, Green L, Arbelaez AM, Koller JM, et al. Insulin, Central Dopamine D2 Receptors, and Monetary Reward Discounting in Obesity. PLoS One. 2015;10(7):e0133621 Epub 2015/07/21. 10.1371/journal.pone.0133621
- Breda E, Cavaghan MK, Toffolo G, Polonsky KS, Cobelli C. Oral glucose tolerance test minimal model indexes of beta-cell function and insulin sensitivity. Diabetes. 2001;50(1):150–8. Epub 2001/01/09. .
- Dalla Man C, Yarasheski KE, Caumo A, Robertson H, Toffolo G, Polonsky KS, et al. Insulin sensitivity by oral glucose minimal models: validation against clamp. American journal of physiology. 2005;289(6):E954–9. 10.1152/ajpendo.00076.2005 .
- Mawlawi O, Martinez D, Slifstein M, Broft A, Chatterjee R, Hwang DR, et al. Imaging human mesolimbic dopamine transmission with positron emission tomography: I. Accuracy and precision of D(2) receptor parameter measurements in ventral striatum. J Cereb Blood Flow Metab. 2001;21(9):1034–57. Epub 2001/08/29. 10.1097/00004647-200109000-00002 .
- Cobelli C, Dalla Man C, Toffolo G, Basu R, Vella A, Rizza R. The oral minimal model method. Diabetes. 2014;63(4):1203–13. 10.2337/db13-1198
- Villareal DT, Banks MR, Patterson BW, Polonsky KS, Klein S. Weight loss therapy improves pancreatic endocrine function in obese older adults. Obesity (Silver Spring, Md. 2008;16(6):1349–54. 10.1038/oby.2008.226
- Lopez Vicchi F, Luque GM, Brie B, Nogueira JP, Garcia Tornadu I, Becu-Villalobos D. Dopaminergic drugs in type 2 diabetes and glucose homeostasis. Pharmacological research. 2016;109:74–80. Epub 2016/01/10. 10.1016/j.phrs.2015.12.029 .
- Warne JP, Horneman HF, Ginsberg AB, Pecoraro NC, Foster MT, Akana SF, et al. Mapping brain c-Fos immunoreactivity after insulin-induced voluntary lard intake: insulin- and lard-associated patterns. J Neuroendocrinol. 2007;19(10):794–808. 10.1111/j.1365-2826.2007.01593.x .
- Tellez LA, Medina S, Han W, Ferreira JG, Licona-Limon P, Ren X, et al. A gut lipid messenger links excess dietary fat to dopamine deficiency. Science (New York, NY. 2013;341(6147):800–2. 10.1126/science.1239275 .
- Knudsen K, Hartmann B, Fedorova TD, Ostergaard K, Krogh K, Moller N, et al. Pancreatic Polypeptide in Parkinson's Disease: A Potential Marker of Parasympathetic Denervation. Journal of Parkinson's disease. 2017;7(4):645–52. Epub 2017/09/19. 10.3233/JPD-171189 .
- Garrido-Gil P, Rodriguez-Perez AI, Dominguez-Meijide A, Guerra MJ, Labandeira-Garcia JL. Bidirectional Neural Interaction Between Central Dopaminergic and Gut Lesions in Parkinson's Disease Models. Molecular neurobiology. 2018;55(9):7297–316. Epub 2018/02/07. 10.1007/s12035-018-0937-8 .
- Ter Horst KW, Lammers NM, Trinko R, Opland DM, Figee M, Ackermans MT, et al. Striatal dopamine regulates systemic glucose metabolism in humans and mice. Sci Transl Med. 2018;10(442). 10.1126/scitranslmed.aar3752 .
- Williams JM, Owens WA, Turner GH, Saunders C, Dipace C, Blakely RD, et al. Hypoinsulinemia Regulates Amphetamine-Induced Reverse Transport of Dopamine. PLoS Biol. 2007;5(10):e274 10.1371/journal.pbio.0050274
- Stouffer MA, Woods CA, Patel JC, Lee CR, Witkovsky P, Bao L, et al. Insulin enhances striatal dopamine release by activating cholinergic interneurons and thereby signals reward. Nat Commun. 2015;6:8543 10.1038/ncomms9543
- Mebel DM, Wong JC, Dong YJ, Borgland SL. Insulin in the ventral tegmental area reduces hedonic feeding and suppresses dopamine concentration via increased reuptake. Eur J Neurosci. 2012;36(3):2336–46. 10.1111/j.1460-9568.2012.08168.x
- Lynch WJ, Peterson AB, Sanchez V, Abel J, Smith MA. Exercise as a novel treatment for drug addiction: a neurobiological and stage-dependent hypothesis. Neuroscience and biobehavioral reviews. 2013;37(8):1622–44. 10.1016/j.neubiorev.2013.06.011
- Roseberry AG. Acute fasting increases somatodendritic dopamine release in the ventral tegmental area. J Neurophysiol. 2015;114(2):1072–82. Epub 2015/06/19. 10.1152/jn.01008.2014
- Webb IC, Baltazar RM, Wang X, Pitchers KK, Coolen LM, Lehman MN. Diurnal variations in natural and drug reward, mesolimbic tyrosine hydroxylase, and clock gene expression in the male rat. J Biol Rhythms. 2009;24(6):465–76. 10.1177/0748730409346657 .
Source: PubMed